Eli Lilly Misses onEPS, Beats on Sales - Analyst Blog
July 21 2011 - 6:52AM
Zacks
Eli Lilly &
Company (LLY) reported second quarter adjusted earnings
per share of $1.18, a penny below the Zacks Consensus Estimate and
6 cents below the year-ago earnings of $1.24.
Earnings were hurt by higher
operating expenses, which more than offset the rise in
revenues.
Second quarter revenues increased
9% to $6.3 billion, above the Zacks Consensus Revenue Estimate of
$6.0 billion. Revenues were boosted by increased demand for Eli
Lilly’s major products. Exchange rates also favorably impacted
revenues during the quarter.
Reported earnings (including
special items), declined 12% to $1.07. Reported earnings included
$132.3 million of restructuring costs.
Quarterly
Details
Second quarter revenues increased
mainly due to a 5% volume growth and 4% foreign exchange
fluctuation. Price increases did not have a major impact on revenue
growth. Healthcare reform impacted revenues by $110 million.
US revenues increased 3% to $3.35
billion, mainly due to higher volumes. Higher prices also
contributed to the increase in US revenues. Ex-US revenues
increased 17% to $2.91 billion, mainly due to higher demand and
favorable foreign exchange fluctuations.
During the second quarter, Eli
Lilly’s lead product Zyprexa recorded a 12% increase in revenues,
which came in at $1.41 billion. While US revenues increased 11%,
international market revenues increased 12%, mainly due to
favorable foreign exchange fluctuations.
Products contributing to second
quarter growth included Cymbalta (16% growth to $1 billion),
Humulin (18% growth to $311.8 million), Alimta (11% growth to
$613.4 million) and Cialis (14% growth to $477.2 million). Alimta
continued to perform well in ex-US markets due to increased demand.
Meanwhile, Humulin revenues benefited from increased demand thanks
to Eli Lilly’s partnership with Wal-Mart (WMT) for
Humulin ReliOn.
Eli Lilly’s Animal Health segment
contributed $389.5 million (up 20%) to revenues. Higher demand and
the impact of the acquisition of certain Pfizer animal health
products helped boost Animal Health revenues.
Meanwhile, Gemzar revenues
continued to decline with second quarter sales falling 62% to
$112.4 million. Sales were impacted by the entry of generics in the
US in November 2010. The product is also facing generic competition
in major international markets. Effient posted revenues of $71.7
million with US revenues coming in at $52 million.
Expenses
On the operational front, expenses
increased 12% during the quarter. Research and development
(R&D) expenses were 6% higher, mainly due to costs associated
with late-stage clinical activities. Apart from this, marketing,
selling and administrative expenses increased 16% to $2
billion.
2011
Projection
Eli Lilly increased its 2011
earnings per share guidance range to $4.25-$4.35 from $4.15 - $4.30
per share. The Zacks Consensus Estimate for 2011 is $4.28, well
within the guidance range provided by the company.
Revenue growth is now expected in
mid-single digits as opposed to the previous expectation for 2011
revenues growing in low single digits. Eli Lilly still expects the
US health care reform to impact 2011 revenues by $400 - $500
million.
2011 will be a challenging year for
Eli Lilly with the company losing patent exclusivity on Zyprexa.
Zyprexa sales should erode rapidly from October 2011 with the entry
of generics. Moreover, we expect continued erosion of Gemzar sales
due to generics.
The company expects gross margin as
a percentage of revenue to decline in the range of 2-3 percentage
points. Meanwhile, marketing, selling and administrative expenses
are expected to increase in high-single digits, with research and
development expenses expected to increase in low-single digits. Eli
Lilly expects cash flows to be sufficient for funding capital
expenditures of $700 - $800 million, acquisitions and dividend.
Neutral on Eli
Lilly
We currently have a Neutral
recommendation on Eli Lilly. The stock carries a Zacks #3 Rank
(Hold rating) in the short run. Even though we are concerned about
the generic threat to key products and the lack of a significantly
strong pipeline to offset key patent expirations at Eli Lilly, a
strong performance of the diabetes business should offer some
downside support.
The primary pipeline candidate at
Eli Lilly’s diabetes pipeline is Bydureon. Eli Lilly has
co-developed the candidate with Alkermes, Inc.
(ALKS) and Amylin Pharmaceuticals, Inc. (AMLN).
Bydureon is approved in the European Union and a response to the US
Food and Drug Administration’s complete response letter is slated
for the third quarter of 2011.
The other diabetes candidates at
Eli Lilly include empagliflozin (launch potential in 2014),
dulaglutide (regulatory submission potentially in 2013) and basal
insulins (phase III studies scheduled to commence in the second
half of 2011).
The ramp of blood thinner Effient,
upside from the ImClone deal and Eli Lilly’s focus on emerging
markets should provide a boost to revenues. We are also pleased to
see Lilly pursuing small acquisitions and in-licensing deals to
boost its pipeline.
ALKERMES INC (ALKS): Free Stock Analysis Report
AMYLIN PHARMA (AMLN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
WAL-MART STORES (WMT): Free Stock Analysis Report
Zacks Investment Research
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Apr 2024 to May 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2023 to May 2024